Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11990436 | 0.95 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL11990429 | 0.89 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL17414353 | 0.83 | CHRNB2 (0.32) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL11990393 | 0.82 | DPP4 (0.33) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL11990465 | 0.77 | — | — | |
| SCHEMBL11990411 | 0.77 | — | — | |
| SCHEMBL17301107 | 0.77 | POLB (0.44) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL17414350 | 0.77 | KMT2A (0.34) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL13909534 | 0.76 | DPP4 (0.32) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL15107202 | 0.76 | DPP4 (0.39) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9724682-B2 | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170072390-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-16 | — | — | US | disclosed |
| US-9487472-B2 | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-08 | — | — | US | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160002145-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | PRESIDENT AND FELLOWS OF HARVARD (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ASANA BIOSCIENCES, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-9044482-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-8865741-B2 | Aminoindane compounds and use thereof in treating pain | ASANA BIOSCIENCES, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | TRPA1, TRPV1, TRPV2 | CHRNB2 885/4885CHRNB4 2047/4885CHRNA3 832/4885 |
| US-20170072390-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | FTH1, FLI1, FECH | CHRNB2 3114/4885CHRNB4 3935/4885CHRNA3 3130/4885 |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | IDO1, IDO2, SLC1A2 | CHRNB2 582/4885CHRNB4 1356/4885CHRNA3 1393/4885 |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | IDO1, IDO2, SLC1A2 | CHRNB2 582/4885CHRNB4 1356/4885CHRNA3 1393/4885 |
| US-20160002145-A1 | SYNTHESIS OF ACYCLIC AND CYCLIC AMINES USING IRON-CATALYZED NITRENE GROUP TRANSFER | FTH1, FLI1, FECH | CHRNB2 3114/4885CHRNB4 3935/4885CHRNA3 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.